Navigation Links
Amgen's Second Quarter 2013 Revenues Increased 5 Percent To $4.7 Billion And Adjusted Earnings Per Share (EPS) Increased 3 Percent To $1.89
Date:7/30/2013

ent and future products, sales growth of recently launched products, competition from other products (domestic or foreign), and difficulties or delays in manufacturing our products.  In addition, sales of our products are affected by reimbursement policies imposed by third-party payors, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement.  Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products.  Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities.  We or others could identify safety, side effects or manufacturing problems with our products after they are on the market.  Our business may be impacted by government investigations, litigation and product liability claims.  If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions.  Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors.  We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development.  In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products.  Discovery or identification of new pr
'/>"/>
SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Covance Reports Second Quarter Net Revenue of $592 Million, Pro Forma EPS of $0.78 and Record Adjusted Net Orders of $776 Million
2. Oncology remains most restrictive specialty for second year
3. China Biologic Products to Report Second Quarter 2013 Financial Results
4. Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2013 Second Quarter Financial Results
5. Vanda Pharmaceuticals to Announce Second Quarter 2013 Financial Results on July 31, 2013
6. Webcast Alert: Isis Pharmaceuticals Second Quarter 2013 Financial Results Conference Call
7. VirtualScopics Schedules Second Quarter 2013 Earnings Announcement
8. Luminex Corporation Reports Second Quarter 2013 Results
9. Endo to Announce Second Quarter 2013 Financial Results on August 6, 2013
10. Simcere Pharmaceutical Group to Announce Second Quarter 2013 Financial Results on Tuesday, August 13, 2013
11. PDI, Inc. to Hold Second Quarter 2013 Financial Results Conference Call on Monday, August 5, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: PharmaPoint: Atopic ... Analysis to 2022 http://www.reportlinker.com/p01957657/PharmaPoint-Atopic-Dermatitis---India-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... India Drug Forecast and Market Analysis to ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a leading ... of severely obese patients, today announced initial results ... selective inhibitor of methionine aminopeptidase 2 (MetAP2), in ... of genetic obesity.  These results showed improvements in ...
(Date:1/14/2014)... , Jan. 14, 2014 InformEx, North America,s ... of high-value chemistry, will hold the 30 th edition ... Convention Center from January 21-24. (Logo: ... from top pharmaceutical, fine chemical and specialty chemical companies will ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
(Date:4/22/2014)... percent of all lung cancers are small cell ... develop resistance to chemotherapy. However, researchers at Virginia ... insights into the mechanisms leading to this resistance ... Chemotherapies work primarily by mediating B-cell lymphoma 2 ... cell death. Depending on their function, this family ...
(Date:4/22/2014)... 2014Hemoglobin A1c is the standard measurement for assessing glycemic ... of A1c are typically measured every few months in ... model that accurately estimates A1c using self-monitored blood glucose ... Therapeutics ( DTT ), a peer-reviewed journal from ... free on the DTT website at ...
(Date:4/22/2014)... PHILADELPHIA (April 22, 2014) That person we all seem ... take action? Turns out he or she isn,t unable to ... A study of nearly ... about why neurotic people may avoid making decisions and moving ... if action is positive, favorable, good, they just don,t like ...
(Date:4/22/2014)... -- In parallel with modern man ( Homo sapiens ), ... we lived side by side, such as Neanderthals and the ... sapiens survived. What was it in our genetic makeup ... little is known about our unique genetic makeup as distinguished ... fact that we are the only species among them ,to ...
(Date:4/22/2014)... Disease (IBD), a group of chronic inflammatory disorders of ... affects over 1.4 million people in the U.S., and ... there is no cure. , Now, Cincinnati Cancer ... Susan Waltz, PhD, and scientists in her lab have ... genetic study to document the important function for the ...
Breaking Medicine News(10 mins):Health News:Scientists pinpoint protein that could improve small cell lung cancer therapies 2Health News:Neurotics don't just avoid action: They dislike it 2Health News:What gave us the advantage over extinct types of humans? 2Health News:Two genes linked to inflammatory bowel disease 2
... and predicting the tumours that will metastasize in lymph nodes ... 3rd International Conference on innovative approaches in Head and Neck ... Radboud University Nijmegen Medical Centre, the Netherlands, reported results of ... The study was jointly led by scientists from Nijmegen and ...
... Michigan State University has secured a $7.9 million ... Mozambique through increasing the African nation,s agricultural productivity, ... four-year grant, funded by the U.S. Agency for ... University of Florida. The initiative employs trilateral cooperation, ...
... of the factors reported by those who say they are unhappy ... its kind, published in the launch issue of the new online ... challenge the perception that these patients can no longer enjoy quality ... the authors. The research team quizzed 168 members of the ...
... four new grants to help improve awareness, prevention and ... in China and India. The grants total nearly $1 ... hepatitis-related health disparities in Asia to $8 million USD ... announced at the Asian Pacific Association for the Study ...
... 24 (HealthDay News) -- An analysis of proteins in spinal ... with chronic fatigue syndrome, a new study reports. It ... involve the central nervous system and that protein abnormalities in ... conditions, said the research team, which was led by Dr. ...
... suffer from delirium each year, however the condition goes ... if diagnosed, there is no effective way to treat ... professionals. Researchers, clinicians, and administrators from across ... - 7 for "Advancing Delirium Care through Research," the ...
Cached Medicine News:Health News:Gene expression to distinguish metastasizing from non-metastasizing head and neck cancers 2Health News:$7.9 million grant to improve food security, nutrition in Mozambique 2Health News:Most 'locked-in syndrome' patients say they are happy 2Health News:Bristol-Myers Squibb Foundation awards nearly $1M to HBV, HCV awareness, prevention and care 2Health News:Bristol-Myers Squibb Foundation awards nearly $1M to HBV, HCV awareness, prevention and care 3Health News:Spinal Fluid May Hold Clues to Lyme Disease, Chronic Fatigue Syndrome 2Health News:Advancing delirium care through research 2
Inquire...
Rapid Urease test for the presumptive identification of H. pylori in gastric mucosal biopsies...
... The QuickVue H.pylori gII test is a ... qualitative detection of IgG antibodies specific to ... whole blood. It utilizes a convenient, non-invasive, ... aid physicians in the diagnosis of H.pylori ...
... a visually read, qualitative immunochromatographic method for ... a bacterium that grows in the stomach ... and some gastric cancers. FlexSure HP, available ... serum samples, provides the physician with the ...
Medicine Products: